GNPX - Shares of Genprex Inc. (GNPX) Fall Below Previous 52-Week Low
Genprex Inc. (NASDAQ:GNPX) traded at a new 52-week low today of $2.81. So far today approximately 124,000 shares have been exchanged, as compared to an average 30-day volume of 700,000 shares.
Genprex Inc. has overhead space with shares priced $2.91, or 32.2% below the average consensus analyst price target of $4.29.
Genprex Inc is a clinical-stage gene therapy company. It is focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who have limited treatment options. It works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies to provide novel treatment approaches for patients with cancer and diabetes.
In the past 52 weeks, Genprex Inc. share prices are bracketed by a current low of $2.81 and a high of $7.72 and is now at $2.91.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer